19-Dec-2025
Mirum Files Patent Suits to Block Livmarli Generics
TipRanks (Fri, 19-Dec 4:34 PM ET)
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX
Seeking Alpha News (Fri, 19-Dec 9:18 AM ET)
Mirum Pharmaceuticals Raises Capital via Private Placement
TipRanks (Fri, 19-Dec 9:00 AM ET)
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
Business Wire (Fri, 19-Dec 8:30 AM ET)
Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)
TipRanks (Thu, 18-Dec 6:56 AM ET)
TipRanks (Tue, 16-Dec 7:40 AM ET)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 10-Dec 7:00 PM ET)
Business Wire (Mon, 8-Dec 8:00 AM ET)
Business Wire (Mon, 1-Dec 8:10 AM ET)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire (Tue, 25-Nov 4:02 PM ET)
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Mirum Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRM.
As of December 19, 2025, MIRM stock price climbed to $77.74 with 3,642,432 million shares trading.
MIRM has a beta of 0.83, meaning it tends to be less sensitive to market movements. MIRM has a correlation of 0.13 to the broad based SPY ETF.
MIRM has a market cap of $4.02 billion. This is considered a Mid Cap stock.
Last quarter Mirum Pharmaceuticals reported $133 million in Revenue and $.05 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.19.
In the last 3 years, MIRM traded as high as $79.95 and as low as $17.49.
The top ETF exchange traded funds that MIRM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
MIRM has outperformed the market in the last year with a price return of +89.0% while the SPY ETF gained +18.1%. MIRM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.5% and +13.5%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
MIRM support price is $68.43 and resistance is $72.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRM shares will trade within this expected range on the day.
